$HSIC

Envista, Henry Schein, Align Technology, and Dentsply Sirona reported Q2 earnings. Henry Schein beat revenue and EPS estimates, while Align met revenue expectations but missed guidance. Dentsply Sirona's revenue declined but topped estimates. Stocks reacted negatively post-earnings, with Align down 20.1% and Dentsply down 30.6%.

Envista (NYSE:NVST) reported Q2 revenue of $730.5M, up 7.1% YoY, beating estimates. Align Technology (NASDAQ:ALGN) reported $1.06B, up 4.3% YoY, missing revenue guidance. Henry Schein (NASDAQ:HSIC) reported $3.46B, up 6.7% YoY, beating estimates. Stocks are down since reporting.

A former credit supervisor, Tony Ream, was sentenced to 2.5 years in prison for embezzling $1.6M from Henry Schein, a Melville-based medical supplier. Ream used the funds for personal expenses and a failed business venture, according to U.S. Attorney Joseph Nocella.

HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Fourth Amended and Restated Revolving Credit Facility On September 21, 2026, the Company amended and restated its existing $1 billion revolving credit agreement, dated as of June 6, 2025, by and among the Company, the several

Henry Schein (HSIC) announced a U.S. distribution deal with Applied BioCode for its BioCode MDx-3000 platform. The company faces recalls of dental products due to packaging issues. Analysts project $15.4B revenue and $661.2M earnings by 2029, with a 12% potential upside. Recent recalls add operational scrutiny but are not expected to significantly impact the company's growth narrative.

Henry Schein, Inc. [HSIC] outlined plans to accelerate growth, simplify operations, and improve operating income by $200 million, targeting double-digit EPS growth. The company highlighted strong performance in dental and medical segments, focusing on consumables, private label, and technology. Leadership emphasized disciplined M&A and share buybacks for capital allocation.

Albertini Andrea (CEO, Global Dist. & Tech.) sold (to issuer) 3,984 shares of HENRY SCHEIN INC (HSIC) on 2026-09-08.

Henry Schein (HSIC) became an approved supplier for DermaSensor's FDA-cleared skin cancer detection device, expanding its distribution. Analysts project HSIC's revenue at $15.4B and earnings at $661.2M by 2029, a 9% upside. The partnership supports HSIC's shift toward higher-margin technology offerings, but investors should consider pricing pressures and customer bargaining power.

Henry Schein (HSIC) is identified as a potential value stock with a Zacks Rank #2 (Buy) and a Value grade of A. Its P/E ratio of 13.27 is below its industry average of 17.58, and it shows attractive PEG, P/B, P/S, and P/CF ratios compared to industry averages. The analysis suggests HSIC may be undervalued.

Henry Schein, Inc. (HSIC) reported broad-based growth in Q2, with sales increases across distribution, specialty products, and technology. Management raised its 2026 sales and earnings guidance. HSIC trades at a discount to market benchmarks but faces risks from leverage and execution challenges. The company aims for $200M in operating income improvement by 2026, with savings initiatives underway.